Pantoprazolo Mylan (Pantoprazole Sodium Sesquihydrate)

Pantoprazole, the active ingredient in Pantoprazolo Mylan, is a proton pump inhibitor presented as an oral tablet for oral use. It reduces stomach acid production and is used to treat acid‑related disorders in adults.

GNH USA supplies Pantoprazolo Mylan as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Pantoprazolo Mylan, a proton pump inhibitor, is indicated for conditions involving excess gastric acid secretion. - Gastro‑esophageal reflux disease (GERD): provides symptomatic relief by healing esophageal irritation and reducing reflux episodes. - Erosive esophagitis: promotes healing of acid‑induced esophageal lesions and prevents recurrence. - Zollinger‑Ellison syndrome: controls hyper‑secretion of gastric acid associated with gastrin‑producing tumors. - NSAID‑induced gastric ulcer prevention: reduces risk of ulcer formation in patients requiring long‑term non‑steroidal anti‑inflammatory therapy.

Pantoprazolo Mylan may be associated with a range of adverse reactions, varying from mild to severe.

Common Side Effects: - Headache: mild to moderate intensity. - Diarrhea: loose stools, often transient. - Nausea: feeling of queasiness. - Abdominal pain: discomfort in the stomach area. - Flatulence: increased intestinal gas. - Constipation: reduced bowel movements.

Serious or Rare Side Effects: - Severe allergic reaction (anaphylaxis): rash, swelling, difficulty breathing. - Clostridioides difficile infection: persistent watery diarrhea, abdominal cramping. - Low magnesium levels (hypomagnesemia): muscle cramps, irregular heartbeat. - Bone fractures: increased risk with long‑term use. - Acute interstitial nephritis: kidney inflammation, reduced urine output.

Before prescribing Pantoprazolo Mylan, clinicians should consider several safety and handling precautions. - Assess renal function: dose adjustment may be needed in severe renal impairment. - Evaluate for liver disease: monitor hepatic enzymes in patients with hepatic impairment. - Long‑term use caution: consider risk of osteoporosis‑related fractures with prolonged therapy. - Monitor magnesium: periodic assessment recommended for patients on extended treatment. - Avoid abrupt discontinuation: taper may be required to prevent rebound acid hypersecretion. - Store at ambient temperature: keep below 25 °C, protect from moisture and light in original packaging.

Pantoprazolo Mylan can affect the pharmacokinetics of several co‑administered medicines.

Major Interactions (Avoid): - Ketoconazole or itraconazole: reduced antifungal absorption; avoid concurrent use. - Atazanavir or nelfinavir: decreased antiviral efficacy; contraindicated. - Clopidogrel: diminished antiplatelet effect; consider alternative therapy.

Moderate Interactions (Monitor Closely): - Warfarin: possible increase in INR; monitor coagulation parameters. - Digoxin: elevated serum levels; check digoxin concentrations. - Methotrexate (high dose): reduced renal clearance; monitor for toxicity. - Iron supplements: decreased iron absorption; separate dosing by at least 2 hours.